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Background: Few population-based studies report the changes with time in thyroid function tests in patients
with subclinical hypothyroidism. We compared the risk for developing overt hypothyroidism in patients with
subclinical hypothyroidism and euthyroid controls from the same population of elderly Japanese. We also
sought associations of selected parameters with the development of overt hypothyroidism in the subclinical
hypothyroid and euthyroid groups.
Methods: We measured thyrotropin (TSH) and free thyroxine (T4) levels at baseline examinations performed
from 2000 to 2003 in the cohort of Japanese atomic-bomb survivors and identified 71 patients with spontaneous
subclinical hypothyroidism (normal free T4 and TSH > 4.5 mIU/L without a history of thyroid treatment, mean
age 70 year) and 562 euthyroid controls. We re-examined TSH and free T4 levels an average of 4.2 years later
(range, 1.9–6.9).
Results: The risk for progression to overt hypothyroidism was significantly increased in subclinical hypothyroid
patients (7.0%) compared with control subjects (1.6%) after adjusting for age and sex (odds ratio, 4.56; p = 0.009).
Higher baseline TSH levels were associated with progression from subclinical to overt hypothyroidism ( p = 0.02)
in the multivariate analysis, including age, sex, antithyroid peroxidase antibody, and ultrasonography (US)
findings. The analysis using binary TSH data suggested that a TSH level > 8 mIU/L was a predictive value for
development of overt hypothyroidism ( p = 0.005). On the other hand, serum TSH levels spontaneously nor-
malized in 38 (53.5%) of the patients with subclinical hypothyroidism. In the multivariate analysis, normali-
zation of TSH levels was associated with lower baseline TSH levels ( p = 0.004) and normal and homogenous
thyroid US findings ( p = 0.04). Atomic-bomb radiation dose was not associated with subclinical hypothyroidism
or its course.
Conclusions: Subclinical hypothyroidism was four times more likely to be associated with development of overt
hypothyroidism than euthyroid controls in the sample population of Japanese elderly. TSH levels in half of the
patients normalized spontaneously when assessed after an average follow-up period of 4.2 years. Baseline TSH
level and thyroid US findings are potential predictors of future thyroid function in subclinical hypothyroidism.
Introduction
Subclinical hypothyroidism, as defined by elevatedthyrotropin (TSH) levels along with normal free thyroxine
(FT4) levels, is a common disorder, especially in the elderly.
Its prevalence is 4%–10% (1), increasing with age to 20% (2).
Subclinical hypothyroidism is known to be associated with
progression of overt hypothyroidism (3,4). However, as far as
we know, only one study demonstrated an increased risk for
developing overt hypothyroidism in patients with subclinical
hypothyroidism compared with euthyroid controls in a
population-based study. In the 20-year follow-up of the
Whickham cohort in the United Kingdom, elevated serum
TSH levels ( > 6 mU/L) measured by a first-generation TSH
radioimmunoassay at the baseline period between 1972 and
1974 were predictive of progression to overt hypothyroidism
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(odds ratio versus controls with serum TSH levels £ 6 mU/L,
14; 95% confidence interval, 9–24) (5). Recently, an expert
panel defined subclinical hypothyroidism as a serum TSH
level > 4.5 IU/L measured by current assays and normal FT4
(3). In 1- to 10-year follow-up hospital-based studies of pa-
tients with subclinical hypothyroidism with or without un-
derlying thyroid diseases, 18%–33% of patients developed
overt hypothyroidism, whereas TSH levels normalized in 4%–
37% of them (6–9). However, it has not been evaluated whe-
ther and how much subclinical hypothyroidism, defined by
using a current TSH assay, was associated with an increased
risk for developing overt hypothyroidism in comparison with
euthyroid controls. Further, in the elderly, the hormonal
outcome of subclinical hypothyroidism defined as serum TSH
levels > 4.5 IU/L is more uncertain because the upper refer-
ence limit of TSH is likely to increase with age (10).
The prevalence of subclinical hypothyroidism in Japan,
where iodine intake is sufficient, is 5.8% in adults (mean age,
51.3 year) (11) and 10.2% in somewhat older adults (mean age,
58.5 year) (12). Here we investigated a risk for progression to
overt hypothyroidism in subclinical hypothyroidism com-
pared with euthyroid controls among the Japanese elderly




The Adult Health Study (AHS) is a clinical program
established in 1958 by the Radiation Effects Research Foun-
dation (RERF), formerly the Atomic Bomb Casualty Com-
mission, comprising Hiroshima and Nagasaki atomic-bomb
survivors. The AHS biennial health examinations provide
clinical information that is complementary to death and
tumor registry data. A detailed description of the project has
been published elsewhere (13,14). Monitoring of atomic-
bomb survivors has provided the opportunity to evaluate
thyroid function in a population-based study. Among am-
bulatory AHS participants, as shown in Figure 1, 763 of the
1623 who had undergone baseline thyroid examinations be-
tween 2000 and 2003 also underwent follow-up thyroid ex-
aminations between 2004 and 2007 at the Nagasaki RERF
Laboratory. The mean follow-up period was 4.2 years (range,
1.9–6.9). In selecting among the 763 for the present study, we
excluded 67 people who at baseline had a history of thyroid
disease treatment (surgery, radiation, thyroid hormone, or
antithyroid medication) and 7 who had later undergone
thyroid tumor surgery, leaving 689 subjects. Subclinical hy-
pothyroidism was defined as elevated TSH levels ( > 4.5 mIU/
L) based on expert reviews (3,4) and normal FT4 levels (ref-
erence range, 0.71–1.52 ng/dL [9.1–19.6 pmol/L]), and eu-
thyroid control was defined as normal TSH (reference range,
0.45–4.5 IU/mL) and FT4 levels. At the baseline examination,
71 (10.3%) had subclinical hypothyroidism—68 (96%) had
serum TSH levels below 10 mIU/L—whereas 562 (81.6%)
were euthyroid. At the follow-up examination, we defined
patients with overt hypothyroidism as those being treated
with thyroid hormone for decreased FT4 or continuous high
( > 10 mIU/mL) TSH levels and those with decreased FT4 and
elevated TSH levels. We used Dosimetry System 2002 to es-
timate the thyroid atomic-bomb radiation doses of individual
subjects (15). The RERF Human Investigation Committee re-
viewed and approved this study, and all participants pro-
vided written informed consents.
Clinical examination and laboratory methods
At biennial clinical examinations, a trained nurse recorded
information on current and past disease and medications and
drew blood samples for the thyroid function and antithyroid
peroxidase antibody (TPOAb) tests. We determined serum
FT4and TSH levels in a single serum sample with a Lumipulse
1200 analyzer using an immunometric technique based on
chemiluminescence (Fujirebio Diagnostics, Inc.). Lyphochek
Immunoassay TMJ Control (Bio-Rad Laboratories) was used
for quality control at every measurement. We measured
TPOAb with an enzyme-linked immunosorbent assay (Medi-
cal & Biological Laboratories Co., Ltd.), and classified subjects
as positive when their serum concentrations were ‡ 10 IU/mL.
All participants underwent thyroid ultrasonography (US)
(Aloka SSD 2000; Aloka Co Ltd) by two certified ultrasonog-
raphers. US images were recorded on film for review by two
physicians specializing in the thyroid (M.I. and N.S.) without
knowledge of clinical or laboratory data, or thyroid atomic-
bomb radiation dose. Disagreements were resolved by dis-
cussion. Decreased or heterogeneous echogenicity was defined
as a positive US finding that met the generally accepted stan-
dards of diffuse parenchymal hypoechogenicity or a hetero-
geneous echo pattern of the thyroid gland (16,17).
Statistical analysis
We used the v2 test, Fisher exact test, or Wilcoxon rank sum
test to compare variations between groups and multivariate
logistic regression analysis to evaluate the association
FIG. 1. Breakdown of participants into the study subjects.
aAmong 34 subjects of unclassified thyroid function, 1 had
increased FT4 level ( >1.52 ng/dL) and increased TSH level
( >4.5 IU/L), 6 had increased FT4 levels ( >1.52 ng/dL) and
normal TSH levels, and 27 had decreased FT4 levels
( <0.71 ng/dL) and normal TSH level. FT4, free thyroxine;
TSH, thyrotropin.
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between the prognosis of subclinical hypothyroidism and
clinical factors. We conducted analyses with SAS software
running on a UNIX System (SAS/STAT Software, Release
9.0.: SAS Inst. Inc.). All significance tests were two-sided, and
p-values < 0.05 were considered significant.
Results
Baseline clinical characteristics of patients
with subclinical hypothyroidism versus control subjects
Compared with control subjects (Table 1), patients with
subclinical hypothyroidism were older ( p = 0.03, Table 1) and
did not differ in sex ratio ( p = 0.18), duration of follow-up
( p = 0.22), or thyroid atomic-bomb radiation dose ( p = 0.36).
They had significantly higher TSH levels ( p < 0.001), lower
FT4 levels ( p = 0.003), and higher positive rates for TPOAb
( p < 0.001). Thyroid atomic-bomb radiation dose was not as-
sociated with subclinical hypothyroidism in logistic analysis
adjusted for age and sex ( p = 0.62, data not shown).
Progression from subclinical hypothyroidism
to overt hypothyroidism
A comparison of thyroid function at follow-up between
euthyroid controls and patients with subclinical hypothy-
roidism at baseline is shown in Table 2. The rate of progres-
sion to overt hypothyroidism was significantly higher for
patients with subclinical hypothyroidism (7.0%) than for
control subjects (1.6%) ( p = 0.01, Table 2). In logistic regression
analysis adjusted for age and sex, the odds ratio of developing
overt hypothyroidism for patients versus controls was 4.56
(95% confident interval, 1.46, 14.25) ( p = 0.009). Baseline TSH
levels in patients who progressed to overt hypothyroidism
ranged from 5.18 to 11.15. Table 3 shows the number of pa-
tients in three groups at follow-up: normal TSH, subclinical
hypothyroidism, and overt hypothyroidism classified accord-
ing to the basal clinical parameters. The p-value of each pa-
rameter is for heterogeneity of distribution of patients into
three groups at follow-up. In this analysis, TSH level at baseline
was associated with thyroid function at follow-up. In multi-
variate analysis adjusted for age, sex, TPOAb, and US findings,
higher serum TSH levels were significantly associated with
development of overt hypothyroidism ( p = 0.02, Table 4). In the
analysis using binary TSH data (TSH level > 6, 7, 8, and 9
compared with TSH level £ 6, 7, 8, and 9, respectively), TSH
levels > 8 and 9 mIU/L were associated with the development
of overt hypothyroidism ( p = 0.005 and 0.004, respectively),
whereas TSH level > 6 and 7 mIU/L were not (both p = 0.06)
adjusting for age, sex, TPOAb, and US findings, suggesting that
a TSH level more than around 8 mIU/L was a predictive value
for development of overt hypothyroidism. Thyroid atomic-
bomb radiation dose was not associated with progression to
overt hypothyroidism ( p = 0.83, data not shown).
Spontaneous normalization of TSH
At the follow-up examination, 38 (53.5%) of the patients
with subclinical hypothyroidism spontaneously regained
normal TSH levels (Table 2) and TSH levels of all the patients
except 3 decreased > 1.0 mIU/L. Normalization was not
observed in patients whose baseline serum TSH level was
>8 mIU/L and it was observed in 67.6% of patients with
negative US findings and 39.4% with positive US findings
(Table 3). In multivariate analysis, TSH normalization was
negatively associated with serum TSH level ( p = 0.004) and
with positive US findings ( p = 0.04) and was not significantly
associated with age, sex, or TPOAb positivity (Table 4).
Thyroid atomic-bomb radiation dose was not associated with
TSH normalization ( p = 0.89, data not shown).
Discussion
In this 4.2-year (range, 1.9–6.9) follow-up study of the Jap-
anese elderly (mean age, 70 year), we first demonstrated that
subclinical hypothyroidism, defined as TSH levels > 4.5 IU/L,








Age [mean – SD
(range), years]
68 – 7 (54–87) 70 – 6 (55–86) 0.03
Sex (M:F) 200:362 31:40 0.18
TSH (mean – SD,
mIU/L)
2.11 – 0.93 6.10 – 1.71 < 0.001
FT4 (mean – SD,
ng/dL)a
1.01 – 0.16 0.95 – 0.15 0.003
Positive for TPOAb
[n (%)]
63 (11.2) 18 (25.4) < 0.001
Follow-up duration
(mean – SD, years)
4.3 – 0.7 4.2 – 0.6 0.22
Thyroid atomic-bomb
radiation doseb
(mean – SD, mGy)
446 – 618 406 – 703 0.36
< 5 mGy [n (%)] 190 (48.6) 31 (63.3%)
5–1000 mGy [n (%)] 138 (35.3) 10 (20.4%)
> 1000 mGy [n (%)] 63 (16.1) 8 (16.3%) 0.09
aTo convert values to picomoles per liter, multiply by 12.87.
bEstimated thyroid atomic-bomb radiation dose was available for
391 euthyroid controls and 49 patients with subclinical hypothy-
roidism.
M, male; F, female; FT4, free thyroxine; TSH, thyrotropin; TPOAb,
antithyroid peroxidase antibody.
Table 2. Outcomes of Thyroid Function
at Follow-Up








(n = 71) p
Normal thyroid function 511 (90.9) 38 (53.5) < 0.001
Subclinical
hypothyroidism
22 (3.9) 27 (38.0) < 0.001
Overt hypothyroidism 9 (1.6) 5 (7.0) 0.01
Other 20 (3.6)a 1 (1.4)b 0.50
aAmong 20 subjects, 3 had overt hyperthyroidism (TSH <0.45 IU/
L and FT4 >1.52 ng/dL), 4 had subclinical hyperthyroidism (TSH
<0.45 IU/L and normal FT4), 9 had decreased FT4 levels ( <0.71 ng/
dL) and normal TSH levels, and 4 had increased FT4 levels
( >1.52 ng/dL) and normal TSH levels.
bOne patient had subclinical hyperthyroidism.
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was significantly associated with progression to overt hypo-
thyroidism compared with euthyroid controls. The odds ratio
of developing overt hypothyroidism for subclinical hypo-
thyroidism versus euthyroid control was 4.56, which was
lower than that in the Whickham study (odds ratio, 14) (5).
The lower odds ratio may be related to the fact that our study
included more patients with mild subclinical hypothyroidism
because we used a current TSH assay and a lower TSH cut-off
point. Further, older study subjects and shorter observation
periods in this study could also be related to the decreased
odds ratio. Although the present results were obtained in
atomic-bomb survivors, the result can be generalized to the
Japanese population because the atomic-bomb radiation dose
was not associated with subclinical hypothyroidism or its
natural course in this study and no influence on prevalence of
thyroid dysfunction and positivity of thyroid autoantibody
was observed in atomic-bomb survivors in the previous study
(18). Recent reports recommend using an age-, gender-, and
ethnicity-specific TSH reference range (10,19), but a Japanese
age-specific TSH reference range is not available. We were
also concerned that it has not been evaluated whether age-
specific reference range influences risks for various endpoints,
including development of overt hypothyroidism. Therefore,
we used a common definition of subclinical hypothyroidism
as a serum TSH level of 4.5 mIU/L or greater based on expert
reviews (3,4). Using an age-specific TSH cut-off point may
Table 3. Baseline Clinical Parameters in Patients with Subclinical Hypothyroidism
by Thyroid Function at Follow-Up
No. (%) of subjects classified by thyroid function at follow-up
No. of patients Normal TSH Subclinical hypothyroidism Overt hypothyroidism pa
All 70b 38 (54.3) 27 (38.6) 5 (7.1)
Age, year
<70 25 14 (56.0) 9 (36.0) 2 (8.0)
70–75 34 18 (52.9) 13 (38.2) 3 (6.7)
>75 11 6 (54.5) 5 (45.5) 0 0.98
Sex
Male 31 14 (45.2) 14 (45.2) 3 (9.7)
Female 39 24 (61.5) 13 (33.3) 2 (5.1) 0.39
TSH, mIU/L
4.5–8.0 63 38 (60.3) 23 (36.5) 2 (3.2)
>8.0 7 0 4 (57.1) 3 (42.9) < 0.001
TPOAb
Negative 52 26 (50.0) 22 (42.3) 4 (7.7)
Positive 18 12 (66.7) 5 (27.8) 1 (5.6) 0.58
US finding
Negative 37 25 (67.6) 10 (27.0) 2 (5.4)
Positive 33 13 (39.4) 17 (51.5) 3 (9.1) 0.06
Thyroid atomic-bomb radiation dose, mGyc
<5 30 16 (53.3) 12 (40.0) 2 (6.7)
5–1000 10 8 (80.0) 1 (10.0) 1 (10.0)
>1000 8 5 (62.5) 3 (37.5) 0 0.38
aFisher exact test for the distribution of patients into three groups at follow-up: normal TSH, subclinical hypothyroidism, and overt
hypothyroidism.
bTotal is 70, not 71, because one patient had subclinical hyperthyroidism at follow-up.
cEstimated thyroid atomic-bomb radiation dose was available in 48 patients among 70 patients with subclinical hypothyroidism.
US, ultrasonography.
Table 4. Multivariate Analysis of Basal Clinical Parameters Related to Thyroid Function at Follow-Up
Thyroid function at follow-up
Normal TSHa Overt hypothyroidismb
Basal parameter OR (95% CI) p OR (95% CI) p
Age, per 10 years 0.66 (0.25, 1.75) 0.40 0.88 (0.16, 4.72) 0.88
Women 1.05 (0.32, 3.51) 0.93 0.32 (0.03, 3.13) 0.33
TSH, per 1 mU/L 0.41 (0.22, 0.76) 0.004 1.74 (1.09, 2.79) 0.02
Positive for TPOAb 2.16 (0.53, 8.90) 0.29 1.04 (0.08, 14.02) 0.98
Positive US findingc 0.28 (0.08, 0.96) 0.04 1.27 (0.21, 7.75) 0.67
aThe reference group for ‘‘Normal TSH’’ had TSH levels > 4.5 mU/L or thyroid hormone therapy at follow-up.
bThe reference group for ‘‘Overt hypothyroidism’’ had normal FT4 levels and no thyroid hormone therapy at follow-up.
cIndicates presence of diffuse hypoechogenicity or heterogeneous echo pattern of the thyroid in US examination.
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increase the odds ratio of developing overt hypothyroidism in
subclinical hypothyroidism.
Our study showed that baseline serum TSH level, but not
positivity of TPOAb, was prognostic in a multivariate analy-
sis, which is consistent with a prospective Spanish study (9).
We also clearly demonstrated that a TSH level > 8 mIU/L was
predictive for development of overt hypothyroidism. Further,
since the baseline TSH level of all patients in our study whose
condition spontaneously normalized was < 8 mIU/L, care
should be exercised when initiating treatment for such elderly
patients. Our sample population was small, however, and
from an iodine-sufficient country, so an appropriately pow-
ered prospective study is needed to examine the TSH
threshold for predicting hormonal prognosis of subclinical
hypothyroidism in other countries.
On the other hand, about half of the patients spontaneously
regained normal TSH levels. The rate of TSH normalization
from spontaneous subclinical hypothyroidism in this study
population (53.5% over 4.2 years, mean age, 70 year) was
higher than that reported in the United Kingdom (5.5% over 1
year, age, 60 and over) (6) and Spain (37.4% over 2.6 year,
mean age, 62 year) (9) although the results could be less
comparable because of different observation periods. Our
finding of mild subclinical hypothyroidism (TSH < 10 mIU/
L) in 96% of our patients contrasts with the 74% of patients in
the United States population-based study (mean age, 56 year)
(2). Since lower serum TSH levels were significantly associ-
ated with TSH normalization in our multivariate analysis, the
high frequency of mild subclinical hypothyroidism in our
population is probably one of the reasons that TSH level
spontaneously normalized in a large number of patients. In-
deed, all patients showing spontaneous normalization of TSH
levels had serum levels < 8 mIU/L at baseline.
Autoimmune thyroiditis is the major cause of subclinical
hypothyroidism (1). In surveys in Europe, 40%–67% of pa-
tients who had high serum TSH concentrations also had high
serum antibody values (6,20). Further, thyroid autoantibody
was found to have possible prognostic relevance in subclinical
hypothyroidism (5,7,8). However, multivariate analysis ad-
justed by age, sex, TSH levels, and other clinical parameters
did not confirm the association between TPOAb and pro-
gression to overt hypothyroidism, and only TSH level was
significant in a Spanish study (9), which is consistent with our
multivariate analysis. It has been suggested that US thyroid
findings (decreased and heterogenous echogenicity) are as-
sociated with autoiummune thyroid disease and thyroid
dysfunction (16,17,21) and that US is a useful tool for the
diagnosis of antibody-negative autoimmune thyroiditis (22).
Rosário and colleagues recently reported the possibility that
US findings are useful in determining the prognosis of
TPOAb-negative mild subclinical hypothyroidism (23). Our
study clearly demonstrated that a negative US finding, rather
than negative TPOAb, was associated with TSH normaliza-
tion of subclinical hypothyroidism in a multivariate analysis.
Taken together, histological change of the thyroid detected by
US may be more relevant to the prognosis of subclinical hy-
pothyroidism in patients with autoimmune thyroiditis. Our
positive US finding, however, was not significantly associated
with progression to overt hypothyroidism, probably because
of the small case number.
In the present study, the positive rate for TPOAb was only
25.4% in patients with subclinical hypothyroidism, which was
much lower than that in the Spanish hospital-based study
(76%) (9). A similar low positive rate for TPOAb (20.5%) was
reported in patients with subclinical hypothyroidism in an-
other Japanese population study (11), suggesting that a non-
autoimmune etiology might be also responsible for the mild
subclinical hypothyroidism found in Japan. One possible
etiology is iodine diet. The Japanese consume excessive iodine
(24). Excess iodine intake can induce overt and subclinical
hypothyroidism in autoantibody-negative people (25,26), and
in a Japanese population-based study, overt and subclinical
hypothyroidism (TSH > 5.0 mIU/L) was more prevalent in
individuals with high urinary iodine concentration than in
those with normal urinary iodine concentration among thy-
roid autoantibody-negative patients (27). When iodine intake
was restricted, the serum TSH concentrations returned to
normal in autoantibody-negative patients, but not in auto-
antibody-positive patients (28). Urinary iodine excretion in
the Japanese, however, fluctuates from 0.1 to 30 mg/day,
depending on seaweed intake (29). That might, at least in part,
be related to the high rate of TSH normalization. We could not
confirm the association of iodine diet with TSH level in our
study population, however, because we did not have iodine
consumption data.
A limitation of our study was that thyroid status was based
on a single blood test whose reproducibility was not assessed.
It is possible that some participants with TSH levels around
the cutoff point (4.5 mIU/L) might have been misclassified.
Further, TSH levels of patients with subclinical hypothy-
roidism might have fluctuated for a number of reasons during
the study period and rates of TSH normalization and pro-
gression to overt hypothyroidism would be affected by du-
ration of the observation period. However, one of the
strengths of this study is that we could evaluate the prognosis
of subclinical hypothyroidism, although based on single TSH
determinations, in comparison with euthyroid controls in a
population-based study. A further study conducting mea-
surements of thyroid function at regular intervals is necessary
for better understanding of the natural course of thyroid
function in patients with subclinical hypothyroidism.
In the present study of the Japanese elderly, the risk for
progression to overt hypothyroidism was significantly in-
creased in patients with subclinical hypothyroidism, whereas
about half of the patients spontaneously regained normal TSH
levels. Lower TSH levels and negative US findings were as-
sociated with TSH normalization.
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